2025 Future Summit by Mölnlycke Health Care
Smarter incision care and partnerships are key to enhanced clinical practise and improved patient outcomes.
How can smarter incision care become a frontline defence against healthcare acquired infections? The recent 2025 Future Summit, arranged by Mölnlycke Health Care, highlighted that innovation, education and partnerships are essential to enhancing clinical practice and empowering healthcare professionals to improve post-operative patient outcomes.
The Future Summit held in the Netherlands on 6-7 October gathered over 130 international healthcare professionals from vascular, orthopaedic, general, and plastic surgery specialties.
“At Mölnlycke, we believe that education is a cornerstone of progress, and we were thrilled to bring together such a diverse and accomplished group of experts. It was inspiring to hear how important incisions are for surgeons; how protecting that incision is protecting the hours of work they have put in underneath it,” says Emma Wright, Chief Medical Officer at Mölnlycke Health Care.
Presided over by renowned experts Professor Javad Parvizi and Mr. Ibby Younis, the Future Summit provided a platform to explore cutting-edge advancements, share best practices, and foster interdisciplinary collaboration in wound care and surgical excellence.
A key focus was reducing Surgical Site Infections (SSIs), which remain a significant challenge in post-operative care. Also, undisturbed wound healing versus more frequent dressing changes is an issue that divides the medical profession.
Daniel Chaverri, Orthopaedic Surgeon and President of the Spanish Society of Wounds, agrees.
“The less we manipulate the wound, the better is the chance to avoid infections and other complications. Normally, we put the first dressing on in the operating room and change it after seven days,” he explains.
What can Mölnlycke do to improve the situation?
“Clinicians need a broad wound care portfolio to match the wide variety of patients and procedures they manage. It is our job to help support change by demonstrating the significant value our innovative solutions, such as Avance Solo, Mepilex Border Post-Op and Granudacyn, bring to clinical protocols and patient outcomes,” Nick Rothwell explains.
Protecting patients and clinicians from healthcare acquired conditions such as infections and pressure ulcers is at the very core of Mölnlycke’s offering and a cornerstone of sustainable healthcare delivery. Every infection, injury, or complication adds pressure—both in terms of cost and time—to overstretched systems and puts patients and healthcare professionals at risk. By empowering clinicians with the latest evidence and practical knowledge, Mölnlycke helps prevent incidents that negatively impact patients’ quality of life, reduce variation in care, and support more sustainable healthcare systems.
Learn more about Mölnlycke Health Care’s Wound Care portfolio here.
Latest news
Read all news-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China.